Premium
Regional blood flow and neurohormonal responses to milrinone in congestive heart failure
Author(s) -
Cody Robert J,
Kubo Spencer H,
Covit Andrew B,
Müller Franco B,
Rutman Howard,
Leonard Daniel,
Laragh John H,
Feldschuh Joseph,
Preibisz Jacek
Publication year - 1986
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1986.23
Subject(s) - milrinone , vascular resistance , renal blood flow , medicine , heart failure , plasma renin activity , hemodynamics , cardiac index , cardiology , renal function , pulmonary wedge pressure , blood pressure , cardiac output , endocrinology , renin–angiotensin system
We measured systemic hemodynamics, regional blood flow, and neurohormonal parameters in 13 patients with severe chronic congestive heart failure before and after 1 month of therapy with oral milrinone, a bipyridine cardiotonic agent. After milrinone there were significant reductions in pulmonary wedge pressure (27 ± 2 to 19 ± 3 mm Hg; P < 0.02) and systemic vascular resistance (1866 ± 152 to 1393 ± 93 dyne · sec/cm 5 ; P < 0.05) that were associated with increases in cardiac index (1.85 ± 0.15 to 2.47 ± 0.20 L/min/m 2 ; P < 0.02). There was a marked improvement in forearm blood flow (1.98 ± 0.14 to 3.02 ± 0.16 ml/min/dl; P < 0.01) and a reduction in forearm vascular resistance (45 ± 3 to 30 ± 3 U; P<0.01). Overall there was no significant change in renal blow flow, renal vascular resistance, or glomerular filtration rate. However, there was a heterogeneous response of renal blood flow and glomerular filtration rate, such that both were directly correlated with the magnitude of increase of cardiac index (r = 0.587 [P < 0.05] and r = 0.721 [P < 0.01], respectively). After milrinone there were no significant overall or subgroup changes in urinary sodium excretion, blood volume, plasma renin activity, urinary aldosterone levels, plasma or platelet vasopressin levels, or plasma norepinephrine levels. Thus 1 month of therapy with milrinone improves systemic and forearm hemodynamics, but its effects on renal blood flow and function were heterogeneous. These heterogeneous effects on regional blood flow may depend on the relative vasodilator and inotropic effects of milrinone. Clinical Pharmacology and Therapeutics (1986) 39, 128–135; doi: 10.1038/clpt.1986.23